New Mathematical Map Reveals Why Drugs Fail in Patchy Tumors and Biofilms

One of the most stubborn puzzles in medicine and microbiology is deceptively simple to state: why does a drug that should, on paper, wipe out a population of cells sometimes fail to do so? Chemotherapy regimens are designed around average growth rates, antibiotic doses around mean inhibitory concentrations, and yet tumors relapse and bacterial biofilms persist. A new theoretical study published in PLOS Complex Systems by Zhijian Hu and Kevin Wood argues that the answer lies not in the average, but in the architecture—specifically, in the way cells are distributed across spatially structured microhabitats where drug concentrations and growth conditions vary from place to place. The work offers a rigorous mathematical framework for predicting whether a population will be cleared or will persist under spatially heterogeneous treatment, and, more strikingly, for steering that outcome by choosing where to deliver the drug.

The biological motivation is broad. Bacteria colonizing a surface and metastatic cancer cells spreading through an organ both face the same fundamental situation: they grow, they migrate, and they occupy patchy environments in which conditions differ sharply from one microhabitat to the next. Migration creates the structure itself, linking colonies into networks that can be critical for colonization or metastasis. When a drug is applied, it too is distributed unevenly, penetrating some sites well and others poorly. The interplay between growth, migration, and this spatial heterogeneity makes population-level responses remarkably difficult to predict. Two environments with the same spatially averaged growth rate can produce opposite fates—one collapsing under treatment, the other persisting—because connectivity and the placement of low-drug refuges matter as much as the mean.

Hu and Wood’s central contribution is a minimal growth-migration model that captures population dynamics on discrete microhabitat structures under spatial drug heterogeneity. Each microhabitat is treated as a node with its own local growth rate, determined in part by the local drug concentration, and nodes are connected by migration pathways whose strengths encode how easily cells move between sites. The model is deliberately stripped down, containing only the essential ingredients of growth and movement, which is precisely what allows the authors to extract exact, general results rather than case-by-case simulations. The question they pose is the clinically urgent one: given a particular spatial arrangement of growth rates and drug exposures, will the total population grow or decline?

The mathematical machinery that answers this question is the most technically striking part of the paper. The authors apply a kernel transformation that maps the original, possibly complicated, microhabitat structure onto an effective fully connected graph, in which every site is linked to every other. On this transformed graph they derive a new exact criterion for population response, expressed in terms of a regularized Laplacian kernel reweighted by the local growth rates. In plain terms, the criterion condenses the entire spatial problem—every node, every migration link, every local drug concentration—into a single mathematical object whose properties determine the population’s fate. If the reweighted kernel satisfies a specific condition, the population is guaranteed to decline; if it fails, growth is possible.

This criterion is not merely an abstract formula. The authors show that it connects directly to a concept from network science called forest closeness centrality, a measure of how centrally located nodes are within the connectivity structure of a graph. Through this connection they obtain analytical bounds and sufficient conditions for population growth or decline, meaning they can certify outcomes without simulating the dynamics at all. This is a significant practical advantage: instead of running many stochastic simulations of cell growth and migration under each candidate treatment plan, one can evaluate a kernel-based quantity and know immediately whether the strategy is guaranteed to push the population toward extinction.

Among the qualitative insights the framework delivers, one stands out for its counterintuitive flavor: higher structural connectivity, such as increased migration between microhabitats, generally promotes population decline under treatment. Intuition might suggest the opposite—that well-connected colonies should be more robust, since cells from drug-protected refuges could continually reseed vulnerable sites. The mathematics shows, however, that migration also drags cells out of safe havens and into drug-exposed territory, mixing the population so that no subpopulation can remain sheltered. In the effective fully connected picture, strong connectivity spreads the lethal influence of high-drug, low-growth regions throughout the network. For treatment design, this suggests a provocative principle: rather than trying to isolate and starve each lesion or colony separately, enhancing the coupling between microhabitats—so that the drug’s effect propagates—can be a route to clearance.

The framework also addresses the inverse problem: not just predicting the response to a given drug distribution, but designing the optimal spatial assignment of drug to guarantee population decline. The authors show that this optimization reduces to selecting interconnected subcores in the effective complete graph—compact, mutually reinforcing sets of microhabitats whose combined treatment overwhelms the population. This geometric characterization turns a potentially intractable continuous optimization into a combinatorial selection problem with clear structure. Moreover, the authors handle the realistic complications that clinicians and microbiologists actually face: when only some microhabitats can be targeted, or when the drug distribution is unknown, they identify strategies that nonetheless ensure decline, providing robust guarantees under partial control and uncertainty.

To demonstrate the clinical relevance of the theory, the authors apply it to a parameterised model of colorectal cancer metastasis under systemic chemotherapy. Metastatic colorectal cancer commonly seeds multiple organs, each with distinct drug penetration characteristics, and systemic chemotherapy exposes all sites to the same regimen. When the framework is applied to this multi-organ setting, it identifies the lung as a critical growth reservoir: a site where poor drug penetration allows the metastatic population to sustain itself even when the spatially averaged drug response would predict decline. This is exactly the failure mode the theory was built to expose—an average-based calculation says the population should shrink, but the spatial structure says otherwise, because one poorly penetrated sanctuary continuously replenishes the rest.

The implication of that finding is concrete and testable: lung-targeted drug delivery emerges as a route to robust clearance in this model. By improving penetration at the critical reservoir, the spatially averaged prediction and the true population-level response can be brought back into agreement, and the guarantee of decline that the kernel criterion provides can actually be met. The authors are careful to frame this as a theoretical illustration on a parameterised model rather than a treatment recommendation, but the logic is general. Any metastatic or biofilm-associated disease in which drug penetration varies across sites could be analyzed the same way, and the framework would flag which specific sites must be better targeted for the treatment to succeed.

Taken together, the study offers a new theoretical perspective on drug response in spatially structured populations and a practical toolkit for optimizing spatially explicit dosing strategies in heterogeneous environments. Its exact criterion, its connection to network centrality, and its guarantees under partial control elevate the work beyond simulation-based studies of spatial heterogeneity, giving researchers a way to certify outcomes analytically. As single-cell and spatial profiling technologies continue to reveal how thoroughly heterogeneous tumors and microbial communities really are, tools of this kind—ones that treat spatial structure as the central object rather than a nuisance—may become essential to the design of therapies that work not just on average, but everywhere the disease actually lives.

Subject of Research: Population-level drug response in spatially heterogeneous microhabitat structures

Article Title: Deciphering and steering population-level response under spatial drug heterogeneity on microhabitat structures

Article References: Hu, Z., & Wood, K. (2026). Deciphering and steering population-level response under spatial drug heterogeneity on microhabitat structures. PLOS Complex Systems, 3(6), e0000113. https://doi.org/10.1371/journal.pcsy.0000113

Image Credits: AI Generated

DOI: 10.1371/journal.pcsy.0000113

Keywords: spatial heterogeneity, growth-migration model, microhabitat, drug response, Laplacian kernel, network centrality, metastasis, colorectal cancer, chemotherapy, drug penetration, population dynamics, dosing strategy